1. Home
  2. SFM vs INCY Comparison

SFM vs INCY Comparison

Compare SFM & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SFM
  • INCY
  • Stock Information
  • Founded
  • SFM 2002
  • INCY 1991
  • Country
  • SFM United States
  • INCY United States
  • Employees
  • SFM N/A
  • INCY N/A
  • Industry
  • SFM Food Chains
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • SFM Consumer Staples
  • INCY Health Care
  • Exchange
  • SFM Nasdaq
  • INCY Nasdaq
  • Market Cap
  • SFM 10.9B
  • INCY 17.0B
  • IPO Year
  • SFM 2013
  • INCY 1993
  • Fundamental
  • Price
  • SFM $81.96
  • INCY $105.55
  • Analyst Decision
  • SFM Buy
  • INCY Buy
  • Analyst Count
  • SFM 14
  • INCY 19
  • Target Price
  • SFM $138.64
  • INCY $89.19
  • AVG Volume (30 Days)
  • SFM 3.4M
  • INCY 2.8M
  • Earning Date
  • SFM 10-29-2025
  • INCY 10-28-2025
  • Dividend Yield
  • SFM N/A
  • INCY N/A
  • EPS Growth
  • SFM 49.03
  • INCY 3878.02
  • EPS
  • SFM 5.15
  • INCY 5.90
  • Revenue
  • SFM $8,653,696,000.00
  • INCY $4,813,105,000.00
  • Revenue This Year
  • SFM $15.50
  • INCY $19.33
  • Revenue Next Year
  • SFM $10.24
  • INCY $10.47
  • P/E Ratio
  • SFM $15.88
  • INCY $17.64
  • Revenue Growth
  • SFM 16.60
  • INCY 18.09
  • 52 Week Low
  • SFM $75.75
  • INCY $53.56
  • 52 Week High
  • SFM $182.00
  • INCY $109.28
  • Technical
  • Relative Strength Index (RSI)
  • SFM 32.37
  • INCY 68.24
  • Support Level
  • SFM $77.87
  • INCY $91.16
  • Resistance Level
  • SFM $82.53
  • INCY $109.28
  • Average True Range (ATR)
  • SFM 3.47
  • INCY 4.59
  • MACD
  • SFM 0.22
  • INCY 0.49
  • Stochastic Oscillator
  • SFM 19.93
  • INCY 80.28

About SFM Sprouts Farmers Market Inc.

Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: